News
-
-
-
-
-
PRESS RELEASE
Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms BUY rating for CEL-SCI Corporation (ISIN: US1508376076) with USD 8.40 price target. Completion of US manufacturing facility for lead drug Multikine expected in H1 2024